Published mark

Lexeo Therapeutics, Inc.

NASDAQ: LXEO. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:ccd9516a-edef-493f-bd8d-d27dcc94d3c5
SEC CIK
0001907108
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 6, 2026
Newest evidence
May 3, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
R. Nolan TownsendChief Executive Officer
Chair
Steven Altschuler, M.D.
Independent
Not published8 directors published
Published claims
263 distinct sources
Evidence records
90 pinned
Source conflicts
0None open

Built from 3 distinct sources and 9 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

EXECUTIVE APPOINTED

Jose Manuel Otero executive of Lexeo Therapeutics, Inc., effective 2026-04-30.

EffectiveEffective Apr 30, 2026E6

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Chief Operating OfficerJose Manuel OteroApr 2026currentSource reportedE6
Chief Medical OfficerNarinder P. BhallaApr 2026currentSource reportedE8
Chief Medical Officer and Head of ResearchEric Adler, M.D.Not capturedunknownSource reportedE4
Chief Legal OfficerJenny R. Robertson, J.D.Not capturedunknownSource reportedE5
Chief Operating OfficerJose Manuel Otero, Ph.D.Not capturedunknownSource reportedE2
Chief Financial OfficerKyle Rasbach, Ph.D.Not capturedunknownSource reportedE7
Chief Financial OfficerLouis TamayoNot capturedunknownSource reportedE2
Chief Medical OfficerNarinder Bhalla, M.D.Not capturedunknownSource reportedE2
Chief Executive OfficerR. Nolan TownsendNot capturedunknownSource reportedE2
Chief Development OfficerSandi See Tai, M.D.Not capturedunknownSource reportedE9

Board of directors

Evidence

8 directors published. Independence determinations are not published for every director.

DirectorStatusSinceCommitteesClaim
Brenda CooperstoneIndependence not published2023None publishedSource reportedE3
Laura Sepp-LorenzinoIndependence not published2026None publishedSource reportedE3
Mette Kirstine AggerIndependence not published2020None publishedSource reportedE3
Paula HJ CholmondeleyIndependence not published2021None publishedSource reportedE3
Reinaldo DiazIndependence not published2005None publishedSource reportedE3
Steven AltschulerIndependence not published2012None publishedSource reportedE3
Tim Van HauwermeirenIndependence not published2024None publishedSource reportedE3
Tolga TangulerIndependence not published2024None publishedSource reportedE3
Brenda Cooperstone, M.D.IndependentNot publishedNone publishedSource reportedE2
Laura Sepp-Lorenzino, Ph.D.IndependentNot publishedNone publishedSource reportedE2
R. Nolan TownsendNot independentNot publishedNone publishedSource reportedE2
Steven Altschuler, M.D.IndependentChairNot publishedNone publishedSource reportedE2

Committees and risk ownership

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerR. Nolan Townsend, Chief Executive Officer
Source reportedE2
company:ccd9516a-edef-493f-bd8d-d27dcc94d3c5:leadership_role:25
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingLXEO (NASDAQ)
Source reportedE1
company:ccd9516a-edef-493f-bd8d-d27dcc94d3c5:security_listing:27
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 6, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameLexeo Therapeutics, Inc.
Source reportedE1
company:ccd9516a-edef-493f-bd8d-d27dcc94d3c5:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:ccd9516a-edef-493f-bd8d-d27dcc94d3c5:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • CommitteesNot reviewed. Committee mandates show where oversight is delegated.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
9 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 6, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    SEC DEF 14A 0001193125-26-193930
    sec def 14a. Published Apr 30, 2026. Retrieved Sep 6, 2026. Cited by 8 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    DEF 14A lxeo-def_14a-2026_proxy.htm
    sec proxy. Published Apr 30, 2026. Retrieved Sep 2, 2026. Cited by 8 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    LXEO executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    LXEO executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    LXEO DEF 14A executive officers
    sec filing. Published Apr 30, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  7. E7
    LXEO executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  8. E8
    LXEO DEF 14A executive officers
    sec filing. Published Apr 30, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  9. E9
    LXEO executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 6, 2026
  • Jose Manuel Otero executive of Lexeo Therapeutics, Inc., effective 2026-04-30.
  • Narinder P. Bhalla executive of Lexeo Therapeutics, Inc., effective 2026-04-30.
  • Laura Sepp-Lorenzino seat on Lexeo Therapeutics, Inc., effective 2026-01-01.
  • Tim Van Hauwermeiren seat on Lexeo Therapeutics, Inc., effective 2024-01-01.
  • Tolga Tanguler seat on Lexeo Therapeutics, Inc., effective 2024-01-01.
  • Brenda Cooperstone seat on Lexeo Therapeutics, Inc., effective 2023-01-01.
  • Paula HJ Cholmondeley seat on Lexeo Therapeutics, Inc., effective 2021-01-01.
  • Mette Kirstine Agger seat on Lexeo Therapeutics, Inc., effective 2020-01-01.
  • Steven Altschuler seat on Lexeo Therapeutics, Inc., effective 2012-01-01.
  • Reinaldo Diaz seat on Lexeo Therapeutics, Inc., effective 2005-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:ccd9516a-edef-493f-bd8d-d27dcc94d3c5, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/lexeo-therapeutics-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership10
  4. Board12
  5. Committees0
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps18
  16. Linked people21
  17. Subject and corrections6
  18. Evidence9
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:ccd9516a-edef-493f-bd8d-d27dcc94d3c5
  • Cite this recordLexeo Therapeutics, Inc.
  • Copy canonical URLregistry.alpha.ac/companies/lexeo-therapeutics-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    Lexeo Therapeutics, Inc.Company
  • Jose Manuel OteroPerson
  • Narinder P. BhallaPerson
  • Eric Adler, M.D.Person
  • Jenny R. Robertson, J.D.Person
  • Jose Manuel Otero, Ph.D.Person
  • Kyle Rasbach, Ph.D.Person
  • Louis TamayoPerson
  • Narinder Bhalla, M.D.Person
  • R. Nolan TownsendPerson
  • Sandi See Tai, M.D.Person
  • Brenda CooperstonePerson
  • Laura Sepp-LorenzinoPerson
  • Mette Kirstine AggerPerson
  • Paula HJ CholmondeleyPerson
  • Reinaldo DiazPerson
  • Steven AltschulerPerson
  • Tim Van HauwermeirenPerson
  • Tolga TangulerPerson
  • Brenda Cooperstone, M.D.Person
  • Laura Sepp-Lorenzino, Ph.D.Person
  • Steven Altschuler, M.D.Person
  • Sections
    OverviewLexeo Therapeutics, Inc.
  • MonitoringLexeo Therapeutics, Inc.
  • LeadershipLexeo Therapeutics, Inc.
  • BoardLexeo Therapeutics, Inc.
  • CommitteesLexeo Therapeutics, Inc.
  • Control and votingLexeo Therapeutics, Inc.
  • Authority to actLexeo Therapeutics, Inc.
  • FinancialsLexeo Therapeutics, Inc.
  • GovernanceLexeo Therapeutics, Inc.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.